Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

3.86
+0.03000.78%
Post-market: 3.890.0300+0.78%17:55 EDT
Volume:747.68K
Turnover:2.87M
Market Cap:249.24M
PE:-3.94
High:3.92
Open:3.78
Low:3.74
Close:3.83
52wk High:8.48
52wk Low:3.74
Shares:64.57M
Float Shares:49.21M
Volume Ratio:1.20
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9796
EPS(LYR):-1.2729
ROE:-52.15%
ROA:-32.77%
PB:1.31
PE(LYR):-3.03

Loading ...

Immuneering Flags New Press Release on Atebimetinib Preclinical Study Publication in Cancer Research

Reuters
·
Jul 22

Immuneering Corp : Needham Raises Target Price to $18 from $11

THOMSON REUTERS
·
Jul 20

Immuneering is Maintained at Buy by Needham

Dow Jones
·
Jul 20

Immuneering Corporation Announces Grants of Inducement Awards

GlobeNewswire
·
Jul 18

Immuneering CFO Andrew Gengos Files Initial Beneficial Ownership Statement

Reuters
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 13

Immuneering Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 08

Immuneering initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Jul 08

Kalaris Appoints Laurie Keating to Board, Replacing Morana Jovan-embiricos

Reuters
·
Jul 07

Top Executive Makes Bold Insider Move on Immuneering Stock

TIPRANKS
·
Jun 25

Immuneering CEO Benjamin Zeskind Acquires 2,400 Shares for $10,948.08

Reuters
·
Jun 25

Immuneering Chief Scientific Officer Brett Matthew Hall buys $25,045 of common shares

Reuters
·
Jun 17

Mizuho Securities Reaffirms Their Buy Rating on Immuneering (IMRX)

TIPRANKS
·
Jun 17

Immuneering Appoints Veteran Biotech Leader as New CFO

TIPRANKS
·
Jun 16

Immuneering Names Andrew Gengos as CFO

MT Newswires Live
·
Jun 15

Immuneering Names Andrew Gengos Chief Financial Officer

Dow Jones
·
Jun 15

Immuneering - Appoints Andrew Gengos as Chief Financial Officer Effective July 16, 2026

THOMSON REUTERS
·
Jun 15

Press Release: Immuneering Appoints Andrew Gengos as Chief Financial Officer

Dow Jones
·
Jun 15

Immuneering Shareholders Approve Directors and Auditor at Meeting

TIPRANKS
·
Jun 12

Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient

MT Newswires Live
·
Jun 11